BioSpace News Archive

HOYA Corporation and a subsidiary through PENTAX Medical division, Pentax of America, Inc. (collectively, “PENTAX” or “the Company”), today finalized a Deferred Prosecution Agreement (DPA) with the U.S. Department of Justice (DOJ) on issues related to the timely filing of Medical Device Reports (MDRs) for PENTAX Medical’s duodenoscopes

Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 766,667 shares of the Company’s common stock, at a purchase price of $6.00 per share, in a registered direct offering priced at-the-market under Nasdaq rules

CDC-approved technique will allow caregivers to use disposable masks up to three times

The initial projections for the flu vaccine market to reach US$8Bn by the end of 2029, is now projected to escalate even higher with the rapidly growing crisis of COVID-19.

Acquisition Creates One-Stop-Shop for Medication Advisory, CE Learning Solutions, Sterile Compounding Best Practices, and Consulting and Educational Strategies for Pharmacists, Pharmacy Technicians, Prescribers, Nurses, and Clinicians

Sharing Negative Science Results Is Key to Neuroscience Advancement

Joseph W. St. Geme, MD, Chair of the Department of Pediatrics and Physician-in-Chief at Children’s Hospital of Philadelphia, has been named the 2020 recipient of the Joseph W. St. Geme, Jr. Leadership Award, an honor that is bestowed by the Federation of Pediatric Organizations and is named after his father, a renowned and celebrated pediatrician.

Zentalis Pharmaceuticals, Inc. announced the closing of its initial public offering of 10,557,000 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase up to 1,377,000 additional shares, at a public offering price of $18.00 per share, for total gross proceeds of approximately $190.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Zentalis.

Idera Pharmaceuticals, Inc. announced entering into an agreement with a fund affiliated with an institutional investor providing for a private placement exempt from the registration requirements of the Securities Act of 1933, as amended, pursuant to which Idera has sold shares of common stock together with accompanying warrants to purchase an additional shares of common stock, for aggregate gross proceeds of $5.0 million.

New information from NCCN, ASCO, ASH, CDC, FDA, and others seeks to provide clear guidance on how to optimally manage cancer-related pain without exacerbating the ongoing opioid crisis--published jointly in the Journal of the National Comprehensive Cancer Network and JCO Oncology Practice.